These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35391572)

  • 21. Evaluation of the compliance with antiemetic guidelines for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancy.
    Uchida M; Nakamura T; Shima T; Mori Y; Yoshimoto G; Kato K; Shimokawa M; Hosohata K; Miyamoto T; Akashi K
    Pharmazie; 2019 Apr; 74(4):250-254. PubMed ID: 30940311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.
    Feinberg B; Gilmore J; Haislip S; Jackson J; Jain G; Balu S; Buchner D
    Support Care Cancer; 2012 Mar; 20(3):615-23. PubMed ID: 21761096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fixed Combination Antiemetic: A Literature Review on Prevention of Chemotherapy-Induced Nausea and Vomiting Using Netupitant/Palonosetron.
    Clark-Snow RA; Vidall C; Börjeson S; Jahn P
    Clin J Oncol Nurs; 2018 Apr; 22(2):E52-E63. PubMed ID: 29547597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy.
    Ito Y; Karayama M; Inui N; Kuroishi S; Nakano H; Nakamura Y; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Hayakawa H; Suda T; Chida K
    Lung Cancer; 2014 Jun; 84(3):259-64. PubMed ID: 24746177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.
    Liau CT; Chu NM; Liu HE; Deuson R; Lien J; Chen JS
    Support Care Cancer; 2005 May; 13(5):277-86. PubMed ID: 15770489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.
    Affronti ML; Schneider SM; Herndon JE; Schlundt S; Friedman HS
    Support Care Cancer; 2014 Jul; 22(7):1897-905. PubMed ID: 24570103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiemetic Guidelines: Using Education to Improve Adherence and Reduce Incidence of CINV in Patients Receiving Highly Emetogenic Chemotherapy.
    Mellin C; Lexa M; Leak Bryant A; Mason S; Mayer DK
    Clin J Oncol Nurs; 2018 Jun; 22(3):297-303. PubMed ID: 29781466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence to antiemetic guidelines and control of chemotherapy-induced nausea and vomiting (CINV) in a large hospital.
    Caracuel F; Muñoz N; Baños U; Ramirez G
    J Oncol Pharm Pract; 2015 Jun; 21(3):163-9. PubMed ID: 24598374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.
    Tsuji D; Suzuki K; Kawasaki Y; Goto K; Matsui R; Seki N; Hashimoto H; Hama T; Yamanaka T; Yamamoto N; Itoh K
    Support Care Cancer; 2019 Mar; 27(3):1139-1147. PubMed ID: 30094732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
    Miura S; Watanabe S; Sato K; Makino M; Kobayashi O; Miyao H; Iwashima A; Okajima M; Tanaka J; Tanaka H; Kagamu H; Yokoyama A; Narita I; Yoshizawa H
    Support Care Cancer; 2013 Sep; 21(9):2575-81. PubMed ID: 23644992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients.
    Dong X; Huang J; Cao R; Liu L
    Med Oncol; 2011 Dec; 28(4):1425-9. PubMed ID: 20602263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Updates in Nausea and Vomiting.
    Cope DG
    Semin Oncol Nurs; 2022 Feb; 38(1):151249. PubMed ID: 35219568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
    Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.
    Nawa-Nishigaki M; Kobayashi R; Suzuki A; Hirose C; Matsuoka R; Mori R; Futamura M; Sugiyama T; Yoshida K; Itoh Y
    Anticancer Res; 2018 Feb; 38(2):877-884. PubMed ID: 29374715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.
    Iihara H; Shimokawa M; Hayashi T; Kawazoe H; Saeki T; Aiba K; Tamura K
    Oncologist; 2020 Feb; 25(2):e373-e380. PubMed ID: 32043774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey.
    Carnio S; Galetta D; Scotti V; Cortinovis DL; Antonuzzo A; Pisconti S; Rossi A; Martelli O; Cecere FL; Lunghi A; Del Conte A; Montagna ES; Topulli J; Pelizzoni D; Rapetti SG; Gianetta M; Pacchiana MV; Pegoraro V; Cataldo N; Bria E; Novello S
    Support Care Cancer; 2018 Jun; 26(6):1841-1849. PubMed ID: 29270827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential.
    Olver I; Clark-Snow RA; Ballatori E; Espersen BT; Bria E; Jordan K
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S33-6. PubMed ID: 20803222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Perceptual gap between oncologists/oncology nurses and patients in the management and impact of chemotherapy/radiotherapy-induced nausea and vomiting: French results of the GAP survey].
    Morin S; Leurs I; Bousquet MN; Scotté F
    Bull Cancer; 2016 May; 103(5):469-77. PubMed ID: 27015797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of clinical practice guideline-recommended antiemetic agents for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients: a systematic review and meta-analysis.
    Patel P; Paw Cho Sing E; Dupuis LL
    Expert Opin Drug Saf; 2019 Feb; 18(2):97-110. PubMed ID: 30640557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.